Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells… Read more
Lyell Immunopharma Inc (LYEL) - Net Assets
Latest net assets as of September 2025: $329.12 Million USD
Based on the latest financial reports, Lyell Immunopharma Inc (LYEL) has net assets worth $329.12 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($407.96 Million) and total liabilities ($78.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $329.12 Million |
| % of Total Assets | 80.67% |
| Annual Growth Rate | -1.27% |
| 5-Year Change | -46.71% |
| 10-Year Change | N/A |
| Growth Volatility | 41.8 |
Lyell Immunopharma Inc - Net Assets Trend (2019–2024)
This chart illustrates how Lyell Immunopharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lyell Immunopharma Inc (2019–2024)
The table below shows the annual net assets of Lyell Immunopharma Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $382.82 Million | -41.55% |
| 2023-12-31 | $654.95 Million | -21.40% |
| 2022-12-31 | $833.25 Million | -10.38% |
| 2021-12-31 | $929.79 Million | +29.42% |
| 2020-12-31 | $718.44 Million | +76.06% |
| 2019-12-31 | $408.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lyell Immunopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 121543500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $29.00K | 0.01% |
| Other Comprehensive Income | $291.00K | 0.08% |
| Other Components | $1.73 Billion | 451.28% |
| Total Equity | $382.82 Million | 100.00% |
Lyell Immunopharma Inc Competitors by Market Cap
The table below lists competitors of Lyell Immunopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RDC Semiconductor Co Ltd
TWO:3228
|
$243.42 Million |
|
VIEMED HLTHCARE INC. O.N.
F:VIJ
|
$243.43 Million |
|
Mennica Polska S.A.
WAR:MNC
|
$243.46 Million |
|
STHREE PLC LS -01
F:S8T
|
$243.47 Million |
|
Rezolve AI PLC
F:O5F
|
$243.36 Million |
|
Zhejiang Zhengyuan Zhihui Technology Co Ltd
SHE:300645
|
$243.32 Million |
|
DREAM UNLIMITED A SV
F:50DA
|
$243.29 Million |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
$243.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lyell Immunopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 654,952,000 to 382,824,000, a change of -272,128,000 (-41.5%).
- Net loss of 342,994,000 reduced equity.
- Share repurchases of 36,011,000 reduced equity.
- Other comprehensive income increased equity by 385,000.
- Other factors increased equity by 106,492,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-342.99 Million | -89.6% |
| Share Repurchases | $36.01 Million | -9.41% |
| Other Comprehensive Income | $385.00K | +0.1% |
| Other Changes | $106.49 Million | +27.82% |
| Total Change | $- | -41.55% |
Book Value vs Market Value Analysis
This analysis compares Lyell Immunopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.69x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $33.10 | $20.14 | x |
| 2020-12-31 | $58.27 | $20.14 | x |
| 2021-12-31 | $76.61 | $20.14 | x |
| 2022-12-31 | $67.45 | $20.14 | x |
| 2023-12-31 | $52.19 | $20.14 | x |
| 2024-12-31 | $29.28 | $20.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lyell Immunopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -562285.25%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-89.60%) is below the historical average (-39.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -31.71% | -19692.09% | 0.00x | 1.36x | $-170.18 Million |
| 2020 | -28.46% | -2636.31% | 0.01x | 1.26x | $-276.32 Million |
| 2021 | -26.91% | -2349.47% | 0.01x | 1.21x | $-343.20 Million |
| 2022 | -21.98% | -216.24% | 0.09x | 1.13x | $-266.44 Million |
| 2023 | -35.82% | -180486.15% | 0.00x | 1.15x | $-300.13 Million |
| 2024 | -89.60% | -562285.25% | 0.00x | 1.28x | $-381.28 Million |
Industry Comparison
This section compares Lyell Immunopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lyell Immunopharma Inc (LYEL) | $329.12 Million | -31.71% | 0.24x | $243.38 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |